Achieving Quiescence with Fluocinolone Implants

McGregor, Freia; Dick, Andrew D; Burke, Tomas R.

doi:10.1159/000513221

Cited by 2 publications

(3 citation statements)

References 20 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While they are more effective and have fewer side effects than steroids ( Gao et al, 2019 ), a significant proportion of patients do not respond well and repeated intravitreal injections are required to maintain the visual benefits ( Engman et al, 2011 ). Steroids generally only have short-term effects, but new DEX and FA sustained-release devices have been developed, such as Ozurdex (DEX implant), Iluvien (FA implant), and YUTIQ (FA implant) ( Testi and Pavesio, 2019 ; McGregor et al, 2021 ), which offer a longer duration of action and can reduce the number of intravitreal injections required (DEX for 4–6 months; FA for 3 years) ( Bandello et al, 2014 ). These steroids implants or inserts are commonly used as a second-line treatment for DME patients without significant response to anti-VEGF therapies ( Tan et al, 2017 ; He et al, 2018 ; Fallico et al, 2021 ), but are also considered as valid therapeutic options in the treatment of RVO-induced macular edema because of their anti-inflammatory, anti-angiogenic, and anti-edema properties ( Haller et al, 2010 ; Haller et al, 2011 ; Castro-Navarro et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Steroid Treatment in Macular Edema: A Bibliometric Study and Visualization Analysis

2022

View full text Add to dashboard Cite

The use of steroids to treat macular edema (ME) is a research hotspot in ophthalmology. We utilized CiteSpace and VOSviewer software to evaluate the Web of Science Core Collection publications and to build visualizing maps to describe the research progress in this topic. There were 3,252 publications for three decades during 1988–2021. The number of studies was low during the first 14 years but has risen consistently in the following two decades. The average publications per year were only 4.8 during 1988–2002, which jumped to 113 per year during 2003–2012, and 227 per year during 2013–2021. These publications came from 83 countries/regions, with the United States, Germany, and Italy leading positions. Most studies were published in Investigative Ophthalmology Visual Science, and Ophthalmology was the most cited journal. We found 9,993 authors, with Bandello F having the most publications and Jonas JB being the most frequently co-cited. According to our research, the most popular keyword is triamcinolone acetonide (TA). Macular edema, diabetic macular edema (DME), retinal vein occlusion (RVO), dexamethasone (DEX), fluocinolone acetonide (FA), and some other keywords were commonly studied in this field. In conclusion, the bibliometric analysis provides a comprehensive overview of steroid hotspots and developmental tendencies in the macular edema study. While anti-VEGF therapy is the first-line treatment for DME and RVO-induced macular edema, steroids implant is a valid option for these DME patients not responding to anti-VEGF therapy and non-DME patients with macular edema. Combined therapy with anti-VEGF and steroid agents is vital for future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Steroid Treatment in Macular Edema: A Bibliometric Study and Visualization Analysis

2022

View full text Add to dashboard Cite

show abstract

“…Current evidence suggests that the 0.2 µg/day FAc implant is effective in reducing the need for subsequent treatment with systemic medication [14,15,19,24,25,58,68,71,72].…”

Section: Systemic Therapiesmentioning

confidence: 99%

“…Despite the good clinical outcomes reported in these trials, they did not provide any information about the etiology of the NIU-PS [14,15]. Since FAc implants have become available in the USA and some European countries, more clinical experience has been gained and more studies evaluating FAc implants in different clinical scenarios have been published [15][16][17][18][19][20][21][22][23][24][25][26][27][28] showing that the FAc implants are effective for preventing recurrence of ocular inflammation in patients with NIU-PS [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations

Pleyer,

Pavesio,

Miserocchi

et al. 2024

J Ophthal Inflamm Infect

View full text Add to dashboard Cite

Background Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) is an inflammatory disease, which can significantly impair visual acuity if not adequately treated. Fluocinolone-acetonide sustained-release-0.2 µg/day intravitreal (FAc) implants are indicated for prevention of relapse in recurrent NIU-PS. The aim here was to provide treating clinicians with some consensus-based-recommendations for the clinical management of patients with NIU-PS with 0.2 µg/day FAc implants. Methods A European-clinical-expert-group agreed to develop a consensus report on different issues related to the use of FAc implants in patients with NIU-PS. Results The Clinical-expert-panel provided specific recommendations focusing on clinical presentation (unilateral/bilateral) of the NIU-PS; systemic involvement of NIU-PS and the lens status. Treatment algorithms were developed; one that refers to the management of patients with NIU-PS in clinical practice and another that establishes the best clinical scenarios for the use of FAc implants, both as monotherapy and as adjuvant therapy. Additionally, the Clinical-expert-panel has provided recommendations about the use of the FAc implants in a clinical-setting. The Clinical-expert-panel also considered the safety profile of FAc implants and their possible implications in the daily practice. Conclusions As more clinical experience has been gained using FAc implants, it was necessary to update the clinical recommendations that guide patient management in the clinic. The current consensus document addresses relevant issues related to the use of FAc implants on different types of patients with various etiologies of NIU-PS, and was conducted to standardize approaches to help specialists obtain better clinical outcomes.

show abstract

Achieving Quiescence with Fluocinolone Implants

Cited by 2 publications

References 20 publications

Steroid Treatment in Macular Edema: A Bibliometric Study and Visualization Analysis

Steroid Treatment in Macular Edema: A Bibliometric Study and Visualization Analysis

Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations

Contact Info

Product

Resources

About